EA201891161A1 - BIFUNCTIONAL MOLECULES CONTAINING POLYETHYLENE GLYCOL TO SUPPRESS CATARACT AND PRESBIOPIA - Google Patents

BIFUNCTIONAL MOLECULES CONTAINING POLYETHYLENE GLYCOL TO SUPPRESS CATARACT AND PRESBIOPIA

Info

Publication number
EA201891161A1
EA201891161A1 EA201891161A EA201891161A EA201891161A1 EA 201891161 A1 EA201891161 A1 EA 201891161A1 EA 201891161 A EA201891161 A EA 201891161A EA 201891161 A EA201891161 A EA 201891161A EA 201891161 A1 EA201891161 A1 EA 201891161A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cataract
presbiopia
suppress
polyethylene glycol
molecules containing
Prior art date
Application number
EA201891161A
Other languages
Russian (ru)
Other versions
EA035402B1 (en
Inventor
Муругаппан Мутхукумар
Original Assignee
Зе Юниверсити Оф Массачусеттс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Юниверсити Оф Массачусеттс filed Critical Зе Юниверсити Оф Массачусеттс
Publication of EA201891161A1 publication Critical patent/EA201891161A1/en
Publication of EA035402B1 publication Critical patent/EA035402B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00—Optical parts
    • G02C7/02—Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04—Contact lenses for the eyes

Abstract

В данном документе описаны способы подавления или обращения прогрессирования формирования катаракты или пресбиопии глаза путем введения бифункциональной молекулы, содержащей замещенный или незамещенный амин, или сукцинимид, или карбоновую кислоту, или изоцианат, или изотиоцианат, или сульфонилхлорид, или альдегид, или карбодиимид, или ацилазид, или ангидрид, или фторбензол, или карбонат, или сложный N-гидроксисукцинимидный эфир, или сложный имидоэфир, или эпоксид или сложный фторфениловый эфир, ковалентно связанные с молекулярным ответвлением. И пресбиопия, и катаракты вызваны агрегацией растворимых белков хрусталика, называемых кристаллинами.This document describes methods of suppressing or reversing the progression of cataract formation or presbyopia of the eye by introducing a bifunctional molecule containing a substituted or unsubstituted amine, or succinimide, or carboxylic acid, or isocyanate, or isothiocyanate, or sulfonyl chloride, or aldehyde, or carbodiimide, or acyl azide, or anhydride, or fluorobenzene, or carbonate, or N-hydroxysuccinimide ester, or imido ester, or epoxide or fluorophenyl ester, covalently bound to molecular phenomenon. Both presbyopia and cataracts are caused by the aggregation of soluble lens proteins called crystallins.

EA201891161A 2015-11-13 2016-11-11 Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia EA035402B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562254863P 2015-11-13 2015-11-13
PCT/US2016/061490 WO2017083619A1 (en) 2015-11-13 2016-11-11 Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia

Publications (2)

Publication Number Publication Date
EA201891161A1 true EA201891161A1 (en) 2018-10-31
EA035402B1 EA035402B1 (en) 2020-06-08

Family

ID=57421950

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891161A EA035402B1 (en) 2015-11-13 2016-11-11 Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia

Country Status (18)

Country Link
US (1) US10736863B2 (en)
EP (1) EP3373921B1 (en)
JP (1) JP6794444B2 (en)
KR (1) KR20180083378A (en)
CN (1) CN108348494A (en)
AU (1) AU2016354479B2 (en)
CA (1) CA3004585A1 (en)
CL (1) CL2018001282A1 (en)
CR (1) CR20180294A (en)
EA (1) EA035402B1 (en)
ES (1) ES2745291T3 (en)
IL (1) IL259027B (en)
MX (1) MX2018005903A (en)
PE (1) PE20181070A1 (en)
SA (1) SA518391553B1 (en)
SG (1) SG11201803606XA (en)
WO (1) WO2017083619A1 (en)
ZA (1) ZA201802978B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151747A1 (en) 2013-03-14 2015-12-18 Univ Massachusetts METHOD TO INHIBIT CATARACTS AND PRESBYCIA
SG11201803606XA (en) 2015-11-13 2018-05-30 Univ Massachusetts Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia
US10220012B2 (en) 2016-06-03 2019-03-05 Joerg H. KRUMEICH Solution for ophthalmology
TWI798452B (en) * 2019-06-17 2023-04-11 晶碩光學股份有限公司 Contact lens product
CN111840225B (en) * 2020-08-12 2021-09-14 陈丽娜 Eye drop for treating glaucoma and preparation method thereof

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526789A (en) 1980-02-29 1985-07-02 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation
US4351826A (en) 1980-02-29 1982-09-28 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using acrylamides
US4665089A (en) 1985-03-21 1987-05-12 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
US4620979A (en) 1985-08-02 1986-11-04 Schachar Ronald A Ophthalmological irrigating solution containing ascorbate
US4771036A (en) 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
CA1269327A (en) 1986-04-24 1990-05-22 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
US5055291A (en) 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4808182A (en) 1986-11-26 1989-02-28 Nestle, S.A. Deswelled, hydrogel intraocular lenses
US5091421A (en) 1987-06-04 1992-02-25 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
US5338545A (en) 1987-06-04 1994-08-16 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
US5614587A (en) 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
DE3906311A1 (en) 1989-02-28 1990-08-30 Adatomed Pharma & Med Treatment system for preventing secondary cataract formation after a cataract operation
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
ATE138914T1 (en) 1990-12-10 1996-06-15 Bio Physio Pharmaceutical Rese INDENO-D-PYRIMIDONE COMPOUNDS FOR USE IN MEDICINE
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
RU94046058A (en) 1992-05-20 1996-10-20 Сендзю Фармасьютикал Ко. Agent for cataract treatment and prophylaxis, method of its synthesis, use of (+)-(2s,3s)-3-[(s)-3-methyl-1-(3-methylbutylcarbamoyl)-butylca- -rbamoyl]-2-oxyrancarboxylic acid, its salt and ethyl ester for preparing agent, method of cataract treatment and prophylaxis, method of an aqueous solution preparing
US5375611A (en) 1993-01-26 1994-12-27 Pharmacia Ab Method for preventing secondary cataract
CN1045383C (en) 1993-04-07 1999-10-06 王慧康 Medicine composite for curing senile cataract
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
ATE315939T1 (en) 1993-11-19 2006-02-15 Univ Sydney METHOD FOR PROPHYLAXIS OR CONTROL OF CATARACT
US5516534A (en) 1993-11-26 1996-05-14 Rensselaer Polytechnic Institute Composition and method for reducing structural defects
US5591773A (en) 1994-03-14 1997-01-07 The Trustees Of Columbia University In The City Of New York Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
EP0712635B1 (en) 1994-05-13 2003-05-02 Kuraray Co., Ltd. Medical polymer gel
DE69629230D1 (en) 1995-03-24 2003-09-04 Ocular Res Of Bonton Inc Hydrogel lens with lipid pre-coating
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JP3599848B2 (en) 1995-09-11 2004-12-08 株式会社メニコン Material for hydrous soft ophthalmic lens, molded article for hydrous soft ophthalmic lens comprising the same, and hydrous soft ophthalmic lens comprising the same and method for producing the same
EP0781777A1 (en) 1995-12-28 1997-07-02 Menicon Co., Ltd. Silicon-containing compound and ocular lens material
DE69714663T2 (en) 1996-06-28 2003-04-10 Ube Industries Process for the production of polybutadiene
US5817630A (en) 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
JPH10339857A (en) 1997-06-05 1998-12-22 Menicon Co Ltd Manufacture of chemical slow controlled releasing contact lens and chemical slow controlled releasing contact lens obtained by the same
US6015787A (en) 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
EP1149909A1 (en) 2000-04-28 2001-10-31 Boehringer Mannheim Gmbh Methods for regulating protein conformation using molecular chaperones
US6103756A (en) 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
CA2389917A1 (en) 1999-11-04 2001-05-10 Kazunori Kataoka A polymer micelle as monolayer or layer-laminated surface
US6835394B1 (en) 1999-12-14 2004-12-28 The Trustees Of The University Of Pennsylvania Polymersomes and related encapsulating membranes
US7977385B2 (en) 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
EP1284743A2 (en) * 2000-05-31 2003-02-26 Cerus Corporation Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity
AU2001223953A1 (en) 2000-12-15 2002-06-24 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine as stabilizing agent of proteins
US6958224B2 (en) 2001-03-28 2005-10-25 Council Of Scientific And Industrial Research Chimeric protein α BNAC crystallin with extraordinarily high chaperone-like activity and a method related to the use thereof
US20030020870A1 (en) 2001-06-27 2003-01-30 Zms, Llc Biomedical molding materials from semi-solid precursors
CN1318093C (en) 2001-09-28 2007-05-30 参天制药株式会社 Injections for eye tissue containing drug bound to polyethylene glycol
JP4838968B2 (en) * 2001-09-28 2011-12-14 参天製薬株式会社 Intraocular injection containing drug-polyethylene glycol conjugate
US20050260259A1 (en) 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US20030223957A1 (en) 2002-04-10 2003-12-04 Schwartz Daniel M. Biodegradable PEG based polymer formulations in ocular applications
US6924154B2 (en) 2002-08-20 2005-08-02 Quest Diagnostics Investments Incorporated Hydrophilic chemilumescent acridinium labeling reagents
JP2004161731A (en) 2002-09-25 2004-06-10 Nof Corp Fixing agent for biorelating substance
CA2517145C (en) 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
CN1621091A (en) 2003-11-28 2005-06-01 付经国 Intestine targeted formulation of PEGylated rotavirus and its synthesizing method
EP1711510A4 (en) 2004-02-05 2008-11-26 Intradigm Corp Rnai therapeutics for treatment of eye neovascularization diseases
US7887847B2 (en) 2004-05-08 2011-02-15 Paul Jr Edward L Nutritional supplement for treatment of ocular diseases
WO2005117987A1 (en) 2004-06-01 2005-12-15 Glazier Alan N Antibody conjugates targeting to ocular proteins
US6945971B1 (en) 2004-07-19 2005-09-20 Gwon Arlene E Controlled ocular lens regeneration
CA2580313C (en) 2004-07-19 2016-03-15 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
AU2005304874A1 (en) * 2004-11-04 2006-05-18 University Of Washington Compositions and methods for treatment of protein misfolding and protein aggregation diseases
US7741311B2 (en) 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
CN1660920A (en) 2005-02-01 2005-08-31 华东理工大学 Polyethyleneglycol acid or active ester connected to omega amino acid at their ends, preparation method and application
US20060252107A1 (en) 2005-02-22 2006-11-09 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
DE102005041570A1 (en) 2005-09-01 2007-03-22 Celares Gmbh Highly branched reagents for modifaction of biopharmaceuticals, their preparation and use
US7832875B2 (en) 2005-09-29 2010-11-16 Virtek Vision International Inc. Modulated diode pumped microchip laser projector
US20080094573A1 (en) 2006-04-04 2008-04-24 Vermette Patrick Surface-modified materials, such as contact lenses, methods and kits for their preparation, and uses thereof
US20070275098A1 (en) 2006-05-19 2007-11-29 T.R.P. Company, Inc, A Nevada Corporation Formulation and methodology for the treatment for eye impairment symptoms
WO2008145721A2 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
WO2009029991A1 (en) 2007-09-07 2009-03-12 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity
EP2213303A4 (en) 2007-10-19 2011-12-28 R Tech Ueno Ltd Pharmaceutical composition for treatment of cataract
KR20100000203A (en) 2008-06-24 2010-01-06 인하대학교 산학협력단 Targeted delivery system for anti-cancer drugs using au nanoparticles
KR20110028636A (en) 2008-06-30 2011-03-21 존슨 앤드 존슨 비젼 케어, 인코포레이티드 Methods and ophthalmic devices used in the treatment of ocular allergies
EP2300514B1 (en) 2008-07-14 2016-03-23 Biocon Limited A method of synthesizing a substantially monodispersed mixture of oligomers
WO2010065024A1 (en) 2008-12-05 2010-06-10 Kador Peter F Topical treatment of cataracts in dogs
WO2010130638A1 (en) 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
EP2512492A1 (en) 2009-12-14 2012-10-24 University of Massachusetts Methods of inhibiting cataracts and presbyopia
WO2011133566A2 (en) 2010-04-19 2011-10-27 University Of Louisville Research Foundation, Inc. Repairing bruch's membrane with hydrogels
EP2635310A2 (en) * 2010-11-05 2013-09-11 Rinat Neuroscience Corp. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN102172410B (en) 2011-01-14 2013-08-07 华南理工大学 Construction method of targeted nano particle transmission system for cancer diagnosis and treatment
CN102634492B (en) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 Polyethylene glycol dog source urate oxidase analogue, and preparation method and applications thereof
WO2012135682A2 (en) 2011-03-31 2012-10-04 Dh Technologies Development Pte. Ltd. Composition, method, and kit for calibrating a mass spectrometer
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
EP3366311B1 (en) * 2011-06-03 2020-02-26 3M Innovative Properties Co. Hydrazino-1h-imidazoquinolin-4-amines and conjugates made therefrom
CA2847336C (en) 2011-09-04 2021-09-07 Glytech, Inc. Glycosylated polypeptide and drug composition containing said polypeptide
RU2014118642A (en) 2011-10-12 2015-11-20 Асцендис Фарма Офтальмолоджи Дивижн А/С PREVENTION AND TREATMENT OF EYE VIOLATIONS
CN102579353B (en) 2012-03-30 2013-12-04 吉林大学 Pegylated liposome of folate-targeted anticancer drug and preparation method
BR112015001150A2 (en) * 2012-07-17 2017-06-27 Univ Michigan non-surgical method for cataract treatment
SG11201501914XA (en) 2012-10-11 2015-05-28 Ascendis Pharma Ophthalmology Division As Vegf neutralizing prodrugs for the treatment of ocular conditions
EP2915001A4 (en) 2012-11-01 2016-05-04 Univ Johns Hopkins Contact lens surface modification with hyaluronic acid (ha) binding peptide for ha accumulation and retention
PE20151747A1 (en) 2013-03-14 2015-12-18 Univ Massachusetts METHOD TO INHIBIT CATARACTS AND PRESBYCIA
WO2014171842A1 (en) 2013-04-19 2014-10-23 Living Cell Technologies New Zealand Limited Biocompatible encapsulation system
JP6646578B2 (en) 2013-12-05 2020-02-14 ウー, ニエンWU, Nian Polymer-carbohydrate conjugates for drug transfer technology
SG11201803606XA (en) 2015-11-13 2018-05-30 Univ Massachusetts Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia

Also Published As

Publication number Publication date
BR112018009582A2 (en) 2018-11-06
SA518391553B1 (en) 2021-03-01
CL2018001282A1 (en) 2018-11-16
WO2017083619A1 (en) 2017-05-18
EP3373921A1 (en) 2018-09-19
JP6794444B2 (en) 2020-12-02
IL259027B (en) 2021-05-31
JP2018536659A (en) 2018-12-13
AU2016354479B2 (en) 2021-10-07
CR20180294A (en) 2018-08-10
MX2018005903A (en) 2019-04-04
EA035402B1 (en) 2020-06-08
CA3004585A1 (en) 2017-05-18
ZA201802978B (en) 2019-07-31
US10736863B2 (en) 2020-08-11
SG11201803606XA (en) 2018-05-30
AU2016354479A1 (en) 2018-05-24
KR20180083378A (en) 2018-07-20
CN108348494A (en) 2018-07-31
EP3373921B1 (en) 2019-08-28
ES2745291T3 (en) 2020-02-28
US20170135972A1 (en) 2017-05-18
IL259027A (en) 2018-06-28
PE20181070A1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
EA201891161A1 (en) BIFUNCTIONAL MOLECULES CONTAINING POLYETHYLENE GLYCOL TO SUPPRESS CATARACT AND PRESBIOPIA
CY1121989T1 (en) PHARMACEUTICAL FORMS OF ANTIBODIES
CY1123407T1 (en) STABLE AQUEOUS PHARMACEUTICAL FORMS OF ADALIMUMBI
MA49013A (en) NEW HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS
AR106466A1 (en) THREE-SPECIFIC AND / OR TRIVALENT UNION PROTEINS FOR THE PREVENTION OR TREATMENT OF HIV INFECTION
CY1119060T1 (en) METHODS OF METHODOLOGICAL MODIFICATION, COMPOSITIONS AND USES OF THESE
BR112018073761A2 (en) single chain variable fragment cd3 binding proteins
MA45189A (en) NEW HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS
EA201892616A1 (en) ANTIBODIES TO PD1 AND LAG3 FOR THE TREATMENT OF MALIGNANT NUMER FORMATION
EA201890899A1 (en) PHARNESIDE X-RECEPTOR MODULATORS
EA201790248A1 (en) MEDIA-ANTIBODY COMPOSITIONS AND METHODS FOR THEIR RECEIVING AND APPLICATION
EA201591176A1 (en) COMPOSITIONS AND METHODS WITH THE USE OF PEPTIDE MARK, CONNECTED WITH HYALURONANE
EA201890125A1 (en) NEW HYDROXY DIFFERENTIAL DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EA201891622A1 (en) NEW AMMONIUM DERIVATIVES, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EA201890423A1 (en) SLIGHT PROTEINS OF THE FACTOR IX, METHODS OF THEIR RECEPTION AND APPLICATION
EA201791733A1 (en) Derivatives of 9H-pyrrolodipyridine
MA48987A (en) SUBSTITUTE INDOLINE DERIVATIVES USED AS DENGUE VIRUS REPLICATION INHIBITORS
EA201691795A1 (en) A METHOD FOR IMPROVING THE SOLUBILITY OF PROTEIN AND PEPTIDE AT THE EXPENSE OF USING A BINDING WITH THE FRAGMENT OF IMMUNOGLOBULIN
EA201892040A1 (en) METHOD OF OBTAINING PEDIATED COMPOUNDS MEDICINAL PREPARATION - LINKER AND THEIR INTERMEDIATE COMPOUNDS
CY1125033T1 (en) METHOTREXATE PREPARATION
EA202092202A1 (en) ROR ANTIBODY CONSTRUCTIONS
EA201790432A1 (en) PROBES FOR VISUALIZATION PROTEIN HANTINGTIN
EA202091046A1 (en) HERBICIDES BASED ON PYRIDINE AND PYRIMIDINE CARBOXYLATE AND METHODS OF THEIR APPLICATION
EA201591677A1 (en) METHOD OF DELAYING THE DEVELOPMENT OF CATARACTS AND PRESBIOPIA
EA202191114A1 (en) PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION